Risen (Shanghai) Pharma Eng Co. Ltd. and Risen (Suzhou) Pharma Tech Co. Ltd. have divulged proteolysis targeting chimera (PROTAC) compounds comprising an E3 ubiquitin ligase binding agents coupled to GTPase KRAS or its mutant targeting moiety through a linker reported to be useful for the treatment of cancer.